Previously, miR-184 has been reported to inhibit malignant glioma progression via directly targeting SND1 (27) and serves as a tumor suppressor in breast cancer by directly targeting multiple proteins involved in PI3K/AKT/mTOR pathway (28). This evidence concerns the gene MTOR and neoplasm.